{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.3"},{"groupId":"OG001","value":"35.3"},{"groupId":"OG002","value":"44.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"description":"Percentage of participants with positive antibodies to JNJ-68284528 were reported.","groups":[{"description":"Participants received a conditioning regimen of cyclophosphamide 300 milligrams per meter square (mg/m\\^2) intravenous (IV) infusion and fludarabine 30 mg/m\\^2 as IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received target dose of JNJ-68284528 0.75\\*10\\^6 chimeric antigen receptor T (CAR-T) cells per kilogram (cells/kg) (range: 0.5-1.0\\*10\\^6 CAR-positive viable cells/kg) as IV infusion.","id":"OG000","title":"Phase 1b (US Population)"},{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received recommended phase 2 dose (RP2D) dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG001","title":"Phase 2 (US Population)"},{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received RP2D dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG002","title":"Phase 2 (Japan Population)"}],"paramType":"NUMBER","populationDescription":"All treated analysis set included all participants who received JNJ-68284528 infusion.","reportingStatus":"POSTED","timeFrame":"Pre dose (Day 1) up to 2 years","title":"Phase 1b and Phase 2: Percentage of Participants With Positive Antibodies to JNJ-68284528","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}